AbCellera and Eli Lilly to assess second COVID-19 antibody (LY-CoV1404) in trials of patients with mild-to-moderate COVID-19

AbCellera announced LY-CoV1404 binds to a rarely mutated region of SARS-CoV-2 spike protein, which neutralizes all currently known variants of virus, including U.K., Brazil, California, South Africa and New York strains, and could signal a game-changer in treatment of patients.

Biospace Inc.